CA3243584A1 - THERAGNOSTICS FOLATE CONJUGATES - Google Patents

THERAGNOSTICS FOLATE CONJUGATES

Info

Publication number
CA3243584A1
CA3243584A1 CA3243584A CA3243584A CA3243584A1 CA 3243584 A1 CA3243584 A1 CA 3243584A1 CA 3243584 A CA3243584 A CA 3243584A CA 3243584 A CA3243584 A CA 3243584A CA 3243584 A1 CA3243584 A1 CA 3243584A1
Authority
CA
Canada
Prior art keywords
compound according
compound
radiometal
folate
dota
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243584A
Other languages
English (en)
French (fr)
Inventor
Viola Groehn
Marie-Luise RENZ
Rudolf Moser
Roger Schibli
Cristina Magdalena Mueller
Luisa Maria Deberle
Anna Elisabeth BECKER
Sara Dorina BUSSLINGER
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3243584A1 publication Critical patent/CA3243584A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3243584A 2022-02-01 2023-01-30 THERAGNOSTICS FOLATE CONJUGATES Pending CA3243584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154652.6 2022-02-01
EP22154652 2022-02-01
PCT/EP2023/052117 WO2023148116A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (1)

Publication Number Publication Date
CA3243584A1 true CA3243584A1 (en) 2023-08-10

Family

ID=80118841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243584A Pending CA3243584A1 (en) 2022-02-01 2023-01-30 THERAGNOSTICS FOLATE CONJUGATES

Country Status (9)

Country Link
US (1) US20250127938A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472677A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504027A (cg-RX-API-DMAC7.html)
KR (1) KR20240146013A (cg-RX-API-DMAC7.html)
CN (1) CN118647412A (cg-RX-API-DMAC7.html)
AU (1) AU2023216406A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243584A1 (cg-RX-API-DMAC7.html)
IL (1) IL314508A (cg-RX-API-DMAC7.html)
WO (1) WO2023148116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025227100A2 (en) * 2024-04-26 2025-10-30 Purdue Research Foundation Targeted delivery of therapeutic agent to retinal pigment epithelium in treatment of ocular diseases

Also Published As

Publication number Publication date
AU2023216406A1 (en) 2024-09-19
KR20240146013A (ko) 2024-10-07
EP4472677A1 (en) 2024-12-11
WO2023148116A1 (en) 2023-08-10
CN118647412A (zh) 2024-09-13
IL314508A (en) 2024-09-01
JP2025504027A (ja) 2025-02-06
US20250127938A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
JP7500551B2 (ja) 前立腺特異的膜抗原(psma)の標識化阻害剤、画像化剤としてのそれらの使用、及びpsma発現がんの処置のための医薬剤
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
CN109053616B (zh) 前列腺特异性膜抗原(psma)的标记的抑制剂及其用途
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
WO2014117001A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US20250108138A1 (en) Theragnostic folate conjugates
Ruser et al. Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111
KR101336071B1 (ko) 암 진단용 mri/ct 이중 조영제 및 그 제조방법
US20250127938A1 (en) Theragnostic folate conjugates
US20140121361A1 (en) Novel n3s1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient
HK40109744A (en) Theragnostic folate conjugates
HK40110380A (en) Theragnostic folate conjugates
JP2024530057A (ja) ネトリン-1検出、コンパニオン検査及び放射線に基づく療法
JP2024519603A (ja) 神経内分泌セラノスティクスのための前駆体および放射性トレーサー
EP4640240A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
EP4282439A1 (en) Radioisotope labeled sstr2-agonists with linkers
JP7816883B2 (ja) 線維症の診断および/またはモニタリングに使用するための化合物
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
HK40054611A (en) Novel tumor antigen binding agents and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240731

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240801

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240801

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240801

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241002

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217